Dear Colleagues:
The National Institutes of Health (NIH) issued the following policy notice at the end of last week. If you have any questions, please contact your Federal Contracts and Grants Officer (https://research.uci.edu/about-or/contact/staff-by-dept-assignment/) or me at warnerj@uci.edu.
- Reminder of Requirement for Certification of IRB Approval
(NOT-OD-26-043)
National Institutes of Health
“This Notice is to remind the extramural research community that NIH requires certification that all nonexempt human subjects research has been reviewed and approved by an appropriate Institutional Review Board (IRB).”
Regards,
Jeff Warner
Senior Director, Sponsored Projects
Office of Research
University of California Irvine
949-824-7654
From: Table of Contents for the NIH Guide for Grants & Contracts <NIHTOC-L@LIST.NIH.GOV> On Behalf Of Guide TOC
Sent: Friday, February 20, 2026 12:05 PM
To: NIHTOC-L@LIST.NIH.GOV
Subject: NIH Guide Notices for 02-20-2026 (The NIH Guide TOC)
NIH Guide for Grants and Contracts (Web Version)
Weekly NIH Guide Notices for February 20, 2026
Policy Notices
- Reminder of Requirement for Certification of IRB Approval
(NOT-OD-26-043)
National Institutes of Health
General Notices
- NIA Intervention Testing Program (ITP) Announces Annual Call for Compounds to Test for Lifespan Extension in Mice
(NOT-AG-25-014)
National Institute on Aging
Notice of Changes to Funding Opportunities
- Notice of Early Expiration of PAR-25-099, “Planning for Product Development Strategy (R34 Clinical Trial Not Allowed)”
(NOT-AI-26-006)
National Institute of Allergy and Infectious Diseases
- Notice of Early Expiration of PAR-25-330, “Role of Defective Proviruses in HIV Persistence (R01 Clinical Trial Not Allowed)”
(NOT-AI-26-007)
National Institute of Allergy and Infectious Diseases
- Notice of Early Expiration of PAR-25-300, “Targeting Cell Surface HIV Envelope for Cell Elimination (R01 Clinical Trial Not Allowed)”
(NOT-AI-26-008)
National Institute of Allergy and Infectious Diseases
- Notice of Early Expiration of PAR-25-316 “Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R21 Clinical Trial Not Allowed)”
(NOT-AI-26-009)
National Institute of Allergy and Infectious Diseases
- Notice of Early Expiration of PAR-25-315, “Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R01 Clinical Trial Not Allowed)”
(NOT-AI-26-010)
National Institute of Allergy and Infectious Diseases
- Notice of Change: Expiration of PAR-25-090 — NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional)
(NOT-DK-26-102)
National Institute of Diabetes and Digestive and Kidney Diseases